Company: IMCR
Filing Date: 2025-04-04
Form Type: DEF 14A
Source: 0001140361-25-012123
Chunk: 121

Company: Immunocore Holdings plc
Filing Date: 2025-04-04
Form: DEF 14A
Chunk 121
---
 June 2032      |     |                  |
|                                  |                  |     | Total Options    |           |     |      33,478 |         |     |        |           |     |              |           |     |              |        |     |          |                  |     |                  |                  |     |                  |
| Ranjeev Krishana(6)              |                  |     | 28 May 2024      |           |     |      12,925 |         |     |  2,513 |           |     |        2,513 |           |     | —            |        |     |   $46.05 |                  |     | 28 May 2027      |                  |     | 27 May 2034      |
|                                  |                  |     | Total Options    |           |     |      12,925 |         |     |        |           |     |              |           |     |              |        |     |          |                  |     |                  |                  |     |                  |
| Total Director Options           |                  |     |                  |           |     |   5,239,155 |         |     |        |           |     |              |           |     |              |        |     |          |                  |     |                  |                  |     |                  |

Notes to the table:

| 1. | Options granted during 2021 were granted at the time of our IPO. The exercise price of $26.00 is equal to the price per ADS sold in the IPO, and the awards have no performance conditions attached. |

A-21

TABLE OF CONTENTS

date. The options granted on 30 October 2020, have a vesting commencement date of 1 April 2020. Twenty-five percent of the shares subject to the 30 October 2020, award vest on the first anniversary of the vesting commencement date (1 April 2021), and the remaining shares vest in quarterly installments thereafter, subject to the officer’s continued service through each vesting date

| 3. | The options granted to Dr. Jallal on 7 January 2019, vesting over a five-year period were modified during 2020 and immediately prior to the IPO. The incremental fair values arising on these modifications for accounting purposes were $3.84 and $5.19, respectively. Twenty five percent of the shares subject to the award vested on the second anniversary of the vest